Cardio-oncology & otherCohort study
Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy
- Retrospective cohort study
- dual-centre
Authors' conclusion
TCE therapy demonstrates a favorable cardiovascular safety profile overall, yet cardiovascular complications during therapy are associated with markedly increased mortality risk.
Study context
- Population
- Patients with cancer treated with bispecific T-cell engagers (T-cell engager (TCEs)), 2016–2024
- Participants
- 567 patients
- Outcome
- Cumulative incidence of on-treatment CV events (HF, arrhythmias, MI, stroke) and CV mortality
Main finding
As reported in the abstract
On-treatment CV events · restricted mean follow-up 248 days
- CV events
- 65
- Cumulative incidence of CV events
- 10.4% (95% CI 8.1-13.1)
- New LV dysfunction
- 2.3%
- New-onset AF
- 2.1%
- CV mortality (2 cases)
- 0.4%
Observational data: associations, not effects.
Further findings
Factors associated with CV events
- CAD the only baseline variable independently associated with CV events
- Grade ≥2 cytokine-release syndrome (CRS) and/or ICANS associated with significant time-dependent increase in CV event risk
All-cause mortality
- CV events significantly associated with higher all-cause mortality, independent of baseline factors and TCE agent
Original publication
Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy. JACC CardioOncol. Published 16 March 2026. doi:10.1016/j.jaccao.2026.01.005
Summarised from the published abstract; every number is checked against it